曲拉西利在广泛期小细胞肺癌中的应用进展

张翠翠 李梦洁 陈鹏

张翠翠, 李梦洁, 陈鹏. 曲拉西利在广泛期小细胞肺癌中的应用进展[J]. 中国肿瘤临床, 2023, 50(19): 1021-1025. doi: 10.12354/j.issn.1000-8179.2023.20230971
引用本文: 张翠翠, 李梦洁, 陈鹏. 曲拉西利在广泛期小细胞肺癌中的应用进展[J]. 中国肿瘤临床, 2023, 50(19): 1021-1025. doi: 10.12354/j.issn.1000-8179.2023.20230971
Cuicui Zhang, Mengjie Li, Peng Chen. Progress in the application of trilaciclib in extensive stage small cell lung cancer[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2023, 50(19): 1021-1025. doi: 10.12354/j.issn.1000-8179.2023.20230971
Citation: Cuicui Zhang, Mengjie Li, Peng Chen. Progress in the application of trilaciclib in extensive stage small cell lung cancer[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2023, 50(19): 1021-1025. doi: 10.12354/j.issn.1000-8179.2023.20230971

曲拉西利在广泛期小细胞肺癌中的应用进展

doi: 10.12354/j.issn.1000-8179.2023.20230971
基金项目: 本文受天津市医学重点学科(与科)建设项目(编号:TJYXZDXK-010A)资助
详细信息
    作者简介:

    张翠翠:专业方向为晚期肺癌的内科治疗

    通讯作者:

    陈鹏 chenpengdoc@sina.com

Progress in the application of trilaciclib in extensive stage small cell lung cancer

Funds: This work was supported by Tianjin Medical Key Disciplines (and Departments) Construction Project (No. TJYXZDXK-010A)
More Information
  • 摘要: 小细胞肺癌恶性程度高、易转移,治疗手段相对匮乏,预后较差。化疗的治疗地位不容忽视,但其常引起骨髓抑制,且补救性措施有时并不会立即起效,并增加新的不良反应风险。对于出现严重骨髓抑制的患者,只能延迟给药或中断治疗,进而影响疗效。曲拉西利(trilaciclib)是一款高效、选择性的CDK4/6抑制剂,在化疗前预防性给药,可诱导骨髓造血干/祖细胞暂时停滞在细胞周期的G1期,从而减少了暴露于化疗药物中造成的损伤。与单一谱系的刺激因子不同,在trilaciclib的作用下,减少了化疗导致的严重外周血中性粒细胞、红细胞以及血小板减少症的发生,并对淋巴系也起到保护作用,改善免疫微环境,提高患者治疗疗效。本文将对trilaciclib药理作用以及在小细胞肺癌中应用进行综述,旨在为临床提供更加全面客观的用药依据。

     

  • 表  1  小细胞肺癌三项Ⅱ期随机对照临床试验汇总常见安全性人群中的不良事件总结 例(%)

    事件trilaciclib联合化疗组(n=122)安慰剂联合化疗组(n=118)增加trilaciclib后发生率变化
    4级以上血液学不良反应19(15.6)62(52.5)
    治疗期间不良事件导致终止的不良事件11(9.0)13(11.0)
    导致住院30(24.6)30(25.4)
    由于化疗导致的骨髓抑制或脓血症导致住院5(4.1)16(13.6)
    致死的不良反应6(4.9)3(2.5)
    不良反应事件(发生率>10%)
     中性粒细胞减少症51(41.8)78(66.1)
     贫血46(37.7)71(60.2)
     恶心41(33.6)39(33.1)
     疲乏41(33.6)32(27.1)
     血小板减少症37(30.3)50(42.4)
     呼吸困难20(16.4)20(16.9)
     发热17(13.9)13(11.0)
     脱发16(13.1)30(25.4)
     腹泻16(13.1)21(17.8)
     食欲减退16(13.1)15(12.7)
     头疼16(13.1)11(9.3)
     便秘14(11.5)23(19.5)
     呕吐11(9.0)19(16.1)
     白细胞减少症10(8.2)28(23.7)
     血小板减少症9(7.4)19(16.1)
     头晕9(7.4)18(15.3)
     中性粒细胞计数减少8(6.6)21(17.8)
    下载: 导出CSV
  • [1] Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3):209-249. doi: 10.3322/caac.21660
    [2] Oronsky B, Reid TR, Oronsky A, et al. What's New in SCLC? A Review[J]. Neoplasia, 2017, 19(10):842-847. doi: 10.1016/j.neo.2017.07.007
    [3] 中华医学会放射肿瘤治疗学分会,中国医师协会放射肿瘤治疗医师分会,中国抗癌协会放射治疗专业委员会,中国临床肿瘤学会肿瘤放疗专家委员会.中国小细胞肺癌放射治疗临床指南(2020版)[J].中华放射肿瘤学杂志,2020,29(8):599-607.
    [4] Liu SV, Reck M, Mansfield AS, et al. Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide (IMpower133)[J]. J Clin Oncol, 2021, 39(6):619-630. doi: 10.1200/JCO.20.01055
    [5] Goldman JW, Dvorkin M, Chen YB, et al. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial[J]. Lancet Oncol, 2021, 22(1):51-65. doi: 10.1016/S1470-2045(20)30539-8
    [6] Cheng Y, Han L, Wu L, et al. Effect of first-line serplulimab vs placebo added to chemotherapy on survival in patients with extensive-stage small cell lung cancer: the ASTRUM-005 randomized clinical trial[J]. JAMA, 2022, 328(12):1223-1232
    [7] 单瑞睿.重组人粒细胞集落刺激因子不良反应的文献分析[J].临床合理用药杂志,2022,15(16):165-168. doi: 10.15887/j.cnki.13-1389/r.2022.16.051
    [8] Marto JP, Strambo D, Livio F, et al. Drugs associated with ischemic stroke: a review for clinicians[J]. Stroke, 2021, 52(10):e646-e659.
    [9] Kozar K, Ciemerych MA, Rebel VI, et al. Mouse development and cell proliferation in the absence of D-cyclins[J]. Cell, 2004, 118(4):477-491. doi: 10.1016/j.cell.2004.07.025
    [10] Malumbres M, Sotillo R, Santamaría D, et al. Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6[J]. Cell, 2004, 118(4):493-504. doi: 10.1016/j.cell.2004.08.002
    [11] Ramsey MR, Krishnamurthy J, Pei XH, et al. Expression of p16Ink4a compensates for p18Ink4c loss in cyclin-dependent kinase 4/6-dependent tumors and tissues[J]. Cancer Res, 2007, 67(10):4732-4741.
    [12] Horsley V, Aliprantis AO, Polak L, et al. NFATc1 balances quiescence and proliferation of skin stem cells[J]. Cell, 2008, 132(2):299-310.
    [13] He SH, Roberts PJ, Sorrentino JA, et al. Transient CDK4/6 inhibition protects hematopoietic stem cells from chemotherapy-induced exhaustion[J]. Sci Transl Med, 2017, 9(387):eaal3986. doi: 10.1126/scitranslmed.aa13986
    [14] Bisi JE, Sorrentino JA, Roberts PJ, et al. Preclinical characterization of G1T28: a novel CDK4/6 inhibitor for reduction of chemotherapy-induced myelosuppression[J]. Mol Cancer Ther, 2016, 15(5):783-793.
    [15] Febres-Aldana CA, Chang JC, Ptashkin R, et al. Rb tumor suppressor in small cell lung cancer: combined genomic and IHC analysis with a description of a distinct Rb-proficient subset[J]. Clin Cancer Res, 2022, 28(21):4702-4713.
    [16] Tan AR, Wright GS, Thummala AR, et al. Trilaciclib plus chemotherapy versus chemotherapy alone in patients with metastatic triple-negative breast cancer: a multicentre, randomised, open-label, phase 2 trial[J]. Lancet Oncol, 2019, 20(11):1587-1601.
    [17] Li C, Hart L, Owonikoko TK, et al. Trilaciclib dose selection: an integrated pharmacokinetic and pharmacodynamic analysis of preclinical data and Phase Ⅰb/Ⅱa studies in patients with extensive-stage small cell lung cancer[J]. Cancer Chemother Pharmacol, 2021,87(5):689-700.
    [18] Lai A, Sorrentino J, Strum J, et al. Abstract 1752: transient exposure of trilaciclib, a CDK4/6 inhibitor, modulates gene expression in tumor immune infiltrates to promote a pro-inflammatory tumor microenvironment[J]. Cancer Research, 2018, 78(13_Suppl):1752.
    [19] Force J, O’Shaughnessy J, Wang LS, et al. Neoadjuvant single-dose trilaciclib prior to combination chemotherapy in patients with early triple-negative breast cancer: safety, efficacy, and immune correlate data from a phase 2 study[J]. Journal of Clinical Oncology, 2023, 41(16_Suppl):603.
    [20] Lai AY, Sorrentino JA, Dragnev KH, et al. CDK4/6 inhibition enhances antitumor efficacy of chemotherapy and immune checkpoint inhibitor combinations in preclinical models and enhances T-cell activation in patients with SCLC receiving chemotherapy[J]. J Immunother Cancer, 2020, 8(2):e000847. doi: 10.1136/jitc-2020-000847
    [21] Chaikovsky AC, Sage J. Beyond the cell cycle: enhancing the immune surveillance of tumors via CDK4/6 inhibition[J]. Mol Cancer Res, 2018, 16(10):1454-1457. doi: 10.1158/1541-7786.MCR-18-0201
    [22] Deng JH, Wang ES, Jenkins RW, et al. CDK4/6 inhibition augments antitumor immunity by enhancing T-cell activation[J]. Cancer Discov, 2018, 8(2):216-233. doi: 10.1158/2159-8290.CD-17-0915
    [23] Goel S, DeCristo MJ, Watt AC, et al. CDK4/6 inhibition triggers anti-tumour immunity[J]. Nature, 2017, 548(7668):471-475. doi: 10.1038/nature23465
    [24] Schaer DA, Beckmann RP, Dempsey JA, et al. The CDK4/6 inhibitor abemaciclib induces a T cell inflamed tumor microenvironment and enhances the efficacy of PD-L1 checkpoint blockade[J]. Cell Rep, 2018, 22(11):2978-2994. doi: 10.1016/j.celrep.2018.02.053
    [25] Weiss JM, Csoszi T, Maglakelidze M, et al. Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ⅰb/randomized phase Ⅱ trial[J]. Ann Oncol, 2019, 30(10):1613-1621. doi: 10.1093/annonc/mdz278
    [26] Cheng Y, Wu L, Huang DZ, et al. EP08.02-078 myeloprotection with trilaciclib in Chinese patients with extensive-stage small cell lung cancer receiving standard chemotherapy(TRACES)[J]. J Thorac Oncol, 2022, 17(9):S437.
    [27] Weiss J, Goldschmidt J, Andric Z, et al. Effects of trilaciclib on chemotherapy-induced myelosuppression and patient-reported outcomes in patients with extensive-stage small cell lung cancer: pooled results from three phaseⅡ randomized, double-blind, placebo-controlled studies[J]. Clin Lung Cancer, 2021, 22(5):449-460.
    [28] Qiu JY, Sheng DD, Lin F, et al. The efficacy and safety of trilaciclib in preventing chemotherapy-induced myelosuppression: a systematic review and meta-analysis of randomized controlled trials[J]. Front Pharmacol, 2023, 14:1157251. doi: 10.3389/fphar.2023.1157251
  • 加载中
表(1)
计量
  • 文章访问数:  120
  • HTML全文浏览量:  15
  • PDF下载量:  28
  • 被引次数: 0
出版历程
  • 收稿日期:  2023-09-05
  • 录用日期:  2023-10-26
  • 修回日期:  2023-10-23

目录

    /

    返回文章
    返回